<DOC>
	<DOCNO>NCT00004827</DOCNO>
	<brief_summary>OBJECTIVES : I . Evaluate potential nutritional docosahexaenoic acid ( DHA ) supplementation normalize level DHA red blood cell , retard progression visual function loss patient early stage X-linked retinitis pigmentosa .</brief_summary>
	<brief_title>Study Docosahexaenoic Acid ( DHA ) Supplementation Patients With X-Linked Retinitis Pigmentosa</brief_title>
	<detailed_description>PROTOCOL OUTLINE : This randomize , parallel , double blind study . Patients receive 2 gel capsule per day either docosahexaenoic acid ( DHA ) enrich oil placebo oil . Oral DHA supplementation continue daily 3 year . All patient follow every 6 month 3 year duration study . Completion date provide represent completion date grant per OOPD record</detailed_description>
	<mesh_term>Retinitis</mesh_term>
	<mesh_term>Retinitis Pigmentosa</mesh_term>
	<criteria>PROTOCOL ENTRY CRITERIA : Disease Characteristics Diagnosis Xlinked retinitis pigmentosa Early stage disease Sufficient cone function determine recordable ERG ( 30 Hz amplitude ; great 0.32 microvolt ) Visual field great 20 degree Sufficient rod function ( great 3.0 microvolt amplitude ) Media clarity sufficient fundus photography Prior/Concurrent Therapy No concurrent use anticoagulant medication Patient Characteristics No chronic metabolic disease may interfere fatty acid metabolism No bleed clinical significance</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 1998</verification_date>
	<keyword>ophthalmologic disorder</keyword>
	<keyword>rare disease</keyword>
	<keyword>retinitis pigmentosa</keyword>
</DOC>